CN1631438A - 0157 bacterium gene engineering multivalence subunit vaccine of human and sensitive animals and its preparing method - Google Patents
0157 bacterium gene engineering multivalence subunit vaccine of human and sensitive animals and its preparing method Download PDFInfo
- Publication number
- CN1631438A CN1631438A CN 200410032026 CN200410032026A CN1631438A CN 1631438 A CN1631438 A CN 1631438A CN 200410032026 CN200410032026 CN 200410032026 CN 200410032026 A CN200410032026 A CN 200410032026A CN 1631438 A CN1631438 A CN 1631438A
- Authority
- CN
- China
- Prior art keywords
- subunit
- stx2b
- intimin
- ehec
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
gene engineering multivalence subunit vaccine for the prevention and treatment of 0157 bacterium of human and sensitive animals and its preparing method, wherein the vaccine employs Intimin and Stx1B, Stx2B AND haemolysin (hly) and their own immunity protective fragment for gene clone expression, then mixing by different combination and various proportion, or fusion at different gene level with different combination and connection pattern for gene recombination engineering bacterium construction, and the high purity fusion protein molecule can be obtained through fermentation and a series of purification procedures.
Description
Technical field
The invention belongs to field of biological pharmacy, relate to the genetic engineering multivalent subunit vaccine that is used for people and prevention of susceptible animal O157 bacterium infection immunity and treatment.
Background technology
EHEC O157 is as a kind of newfound infectiousness pathogenic bacterium, and its harm is just because the outbreak of epidemic that takes place in succession of countries in the world and being familiar with by people gradually in recent years.O157 infects can cause severe complication such as hemolytic uremic syndrome (Hemolytic uremic syndrom, HUS), thrombocytopenic purpura,thrombotic (Thromboricthromobocytopenic porpura, and the people's death of can causing a disease TTP).The treatment that O157 infects is difficulty, and antibacterial therapy impels bacteriotoxin release to cause the incidence rate of complication such as HUS to increase.Development O157 vaccine and its effective inoculation may be prevention infection and effective, the most promising method of the extensive outbreak of epidemic of control.But countries in the world all do not have the O157 vaccine that can be used for people or susceptible animal at present.
Pathogenic adhesion field planting power and two aspects of bacteriotoxin that mainly are embodied in antibacterial of O157 bacterium.Tight adhesion element (Intimin) is the important and special adhesion molecule of this bacterium; intimin and receptor thereof (the plain receptor Tir of transposition tight adhesion) mediation bacterial adhesion is in enterocyte; the extracellular region of Intimin (C-end fragment) is the functional areas with the Tir receptors bind; existing experimental result proved intimin especially the specific antibody of C-end fragment (Intimin-C) can block the adhesion of antibacterial and then make its forfeiture pathogenicity, thereby have stronger immune protective.(1.Son W G and Graham T A, GannonV P J. clinical immunology laboratory diagnosis magazine 2002; 9 (1): 46; 2.Gansheroff L J and Wachtel M R, O ' Brien A D. infection immunity magazine 1999; 67 (12): 6409)
EHEC O157 mainly produces two kinds of shiga toxin toxin, is called shiga toxin I (Stx1) and shiga toxin II (Stx2).In bacterial body, Stx2 is a secretion type expression, and Stx1 expresses in the born of the same parents.Two kinds of toxin are formed by 1 A subunit and 5 B subunits, and the A subunit has toxicity in the cell, can cause protein synthesis to stop with the 28SrRNA effect, and be Escherichia coli O 157: H7 causes the pathologic basis of clinical manifestation; The B subunit is nontoxic, and has the cell binding characteristic, can combine with the cell with special receptor (Gb3), thereby guiding A subunit plays a role.Existing experiment shows that Stx1B and Stx2B have good immunogenicity and immune protective, stimulates body can produce higher protection antibody of tiring, and has toxopexic effect (1.Konadu, people such as EY, infection immunity magazine 1999; 67 (9): 6191-6193; 2.Paola people such as Marcato, infectious disease magazine 2001; 183 (1): 435-443).Stx1B and Stx2B can combine with the antigen presenting cell-dendritic cell with Gb3 receptor (DC cell), the submission and the induce immune response (people such as Nacilla H that help vaccine antigen, international Journal of Immunology, 2003,15 (10) 1161-1171), thereby in this vaccine design with the dual function of immunogen and adjuvant, this is one of innovative point of the present invention just.
(haemolysin is that the duct forms the Lysin family members hly) to the EHEC hemolysin, can form the duct on target cell membrane and kills target cell.The Hly lysed erythrocyte discharges source of iron and breeds fast for antibacterial, is important antibacterial virulence factor.
Although EHEC O157 since confirming as pathogenic bacterium more than 20 year over and done with, still do not have the vaccine development success that can be used for people or susceptible animal so far.One of reason is that the selection of vaccine antigen concentrates on bacteria lipopolysaccharide (1.Konadu, people such as EY, infection immunity magazine 1999; 67 (9): 6191-6193; 2.Konadu, people such as EY, infectious disease magazine, 1998; 177 (2): 383-387.), and the antibody that the O157 lipopolysaccharide is induced has the effect that similar antibiotic equally impels O157 bacterium release lethal shiga toxin, so this technology path is difficult to final success.And the discovery of above protective antigen subunit also fails to enter substantial vaccine research, because the immanoprotection action that single subunit antigen produced is limited, is difficult to the infection of effectively prevention and removing pathogenic bacteria.The present invention is direct important virulence factor at EHEC O157 in the selection of vaccine antigen; and the applied in any combination of emphasizing the relevant protective antigen of a plurality of virulence factors is to produce powerful immanoprotection action; comprehensive this thorny serious illness that tackles experimental results show that respond well.This is two of an innovative point of the present invention.
By the tight adhesion element (Intimin) of the natural generation of enterohemorrhagic Escherichia coli (EHEC) O157, shiga toxin I in conjunction with subunit (Stx1B), shiga toxin II in conjunction with subunit (Stx2B), EHEC hemolysin (haemolysin; hly) etc. the protective antigen subunit is very limited; bacterial antigens component complexity causes the separation purification difficult; and it is also abnormally dangerous to cultivate the O157 bacterium in a large number, so adopt the direct cultivation separation and purification protective antigen of pathogen subunit feasibility poor.The present invention adopts engineered means clonal expression protective antigen subunit, efficiently, safely, be convenient to separation and purification.This is three of an innovative point of the present invention.
Summary of the invention
The present invention is directed to the deficiency that prior art exists; aim to provide enterohemorrhagic Escherichia coli (EHEC) O157 genetic engineering multivalent subunit vaccine of a kind of highly effective and safe and preparation method thereof; this vaccine adopts and the pathogenic closely-related several protective antigen molecules of antibacterial: enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion element (Intimin); shiga toxin I is in conjunction with subunit (Stx1B); shiga toxin II is in conjunction with subunit (Stx2B); EHEC hemolysin (haemolysin; hly) and the immune protective fragment carry out different combinations, obtain to have simultaneously blocking-up adhere to the alternative antigen molecule of antitoxic vaccine.
The present invention with enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion element (Intimin), shiga toxin I in conjunction with subunit (Stx1B), shiga toxin II in conjunction with subunit (Stx2B), EHEC hemolysin (haemolysin; hly) and the immune protective fragment carry out the gene cloning and expression purification or connect construction of fusion protein at gene level, and then obtain the vaccine antigen of the combination of these protective antigen subunit variety classeses, different component ratios and different amalgamation modes.On antigen subunit compound mode, preferably, these protective antigen subunits are connected construction of fusion protein at gene level; On antigen subunit components selection, preferably, vaccine antigen is the plain extracellular region immune protective fragment (Intimin-C) of tight adhesion and shiga toxin II in conjunction with the compositions of subunit (Stx2B) or adds other antigen components on this basis.Therefore more preferably, the plain immune protective fragment of O157 bacterium tight adhesion (Intimin-C) is connected construction of fusion protein in conjunction with subunit (Stx2B) at gene level with shiga toxin II.
The present invention is distinguishing plain extracellular region immune protective fragment (Intimin-C) of clonal expression tight adhesion and shiga toxin I in conjunction with subunit (Stx1B); shiga toxin II is in conjunction with subunit (Stx2B); EHEC hemolysin (haemolysin; hly) on the basis; emphasis has been finished the plain immune protective fragment of tight adhesion (Intimin-C) and has been connected construction of fusion protein in conjunction with subunit (Stx2B) at gene level with shiga toxin II; ways of connecting is: the encoding gene of the plain immune protective fragment of tight adhesion (Intimin-C) is connected with the Stx2B gene by one section nucleotide sequence of coding connexon, thereby obtains fusion rotein Stx2B-Intimin-C.The gene order of encoding said fusion protein is the sequence that has the genetic code degeneracy with it of nucleotide sequence shown in the SEQ ID NO:1 or coding same protein.The structure of described fusion rotein is the aminoacid sequence shown in the SEQ ID NO:2.The gene order of described immune protective fragment Intimin-C is the nucleotide sequence shown in the SEQ ID NO:3.Described encoding gene with the plain immune protective fragment of enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion (Intimin-C300) with shiga toxin II in conjunction with the mode that subunit (Stx2B) gene is connected is: shiga toxin II is positioned at 5 ' end in conjunction with subunit (Stx2B); the encoding gene of the plain immune protective fragment of O157 bacterium tight adhesion (Intimin-C300) is by coding connexon (Gly-Gly-Gly-glycine-serine; GGGGS) one section nucleotide sequence is connected in 3 ' end of Stx2B gene, at 3 ' end connection, the 6 polyhistidyl coded sequences of the plain immune protective fragment coding of Stx2B-IntiminC300 tight adhesion gene.
The present invention adopts and the pathogenic closely-related protective antigen molecule of antibacterial: plain extracellular region (Intimin-C) of tight adhesion and shiga toxin II combine subunit (Stx2B) and carry out amalgamation and expression, have obtained higher expression.Set up the purifying process of fusion rotein Stx2B-Intimin-C, studied its antigen active and immune protective, and confirmed its immunoprophylaxis and treatment of infection effect through zoopery.
The fundamental characteristics of gene engineering recombinant bacterium of the present invention and recombination fusion protein: a. is shaking under bottle condition, and the destination protein expression reaches 50%, under the high density fermentation condition, and destination protein expression about 40%.B. recombiant protein is with the inclusion body formal representation, and molecular weight is 43kDa.C. the recombiant protein of purification can produce higher titer antibody by induced animal, and good immunoprotective effect is arranged.
The monomeric structure of gene engineered subunit of the present invention is seen embodiment 2.
The present invention provides also that a kind of technology is simple and direct, immune protective effect is good, with low cost, to the plain immune protective fragment (Intimin-C) of harmless pattern of fusion enterohemorrhagic Escherichia coli (EHEC) the O157 tight adhesion of people and shiga toxin II preparation method in conjunction with subunit (Stx2B) recombinant vaccine.The preparation method of gene recombinant fusion protein vaccine is as follows:
1. the encoding gene of the Stx2B of clone's enterorrhagia Bacillus coil 0157: H7 and Intimin-C.
1) cultivates enterorrhagia Bacillus coil 0157: H7 (EHEC O157:H7)
2) with the Stx2B of PCR method amplification EHEC O157:H7 and the encoding gene of Intimin-C.
3) clone of PCR product.
4) sequence analysis of PCR product.
2. make up Stx2B and Intimin-C gene Fusion gene.
1) cloned plasmids of usefulness restriction enzyme enzyme action Stx2B and Intimin-C.
2) the enzyme action product separates through agarose gel electrophoresis.
3) the target DNA electrophoresis band on the cutting-out agarose gel.
4) the recovery product cloning of Intimin-C and Stx2B genes of interest is gone into procaryotic cell expression carrier, obtain to contain the recombiant plasmid of Stx2B-Intimin-C gene.
5) will contain the recombinant plasmid transformed escherichia coli of Stx2B-Intimin-C gene.
3. measure the sequence of Stx2B-Intimin-C fusion gene.
4. abduction delivering Stx2B-Intimin-C fusion gene obtains destination protein Stx2B-Intimin-C.
5. the N terminal amino acid sequence of destination protein Stx2B-Intimin-C is analyzed.
6. purifies and separates destination protein Stx2B-Intimin-C.
7. identify the purity of destination protein Stx2B-Intimin-C.
This destination protein Stx2B-Intimin-C is the plain immune protective fragment (Intimin-C) of pattern of fusion enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion and shiga toxin II in conjunction with subunit (Stx2B) recombinant vaccine.
Description of drawings
Fig. 1 is the PCR clonal expansion of the object of the invention gene Stx2B and Intimin-C.
The PCR clonal expansion that shows genes of interest Stx2B and Intimin-C is respond well.
Fig. 2 is that the enzyme action of Stx2B and Intimin-C recombinant expression plasmid is identified.
Fig. 3 is a Stx2B gene recombination bacterium abduction delivering PAGE electrophoretogram
Swimming lane 1: gene recombination bacterium is induced preceding (0hr);
Swimming lane 2-3: gene recombination bacterium induces 2,5hr;
Swimming lane 4: protein molecular weight standard (Marker).Gene recombination bacterium is through the protein expression band of increase is arranged at molecular weight 9KDa place after inducing, and is consistent with the destination protein molecular weight.
Fig. 4 is an Intimin-C gene recombination bacterium abduction delivering PAGE electrophoretogram
Swimming lane 3: gene recombination bacterium is induced preceding (0hr);
Swimming lane 6: protein molecular weight standard (Marker).
Gene recombination bacterium is through the protein expression band of increase is arranged at molecular weight 35KDa place after inducing, and is consistent with the destination protein molecular weight.Analyze through UVP image scanning, induce 5 hours destination protein expressions about 50%.
Fig. 5 is that the enzyme action of fusion gene Stx2B-Intimin-C recombinant expression plasmid is identified.
Swimming lane 7,8 is a recombiant plasmid NcoI/HindIII double digestion product (1200bp).The endonuclease bamhi size is consistent with design, tentatively proves the construction of recombinant plasmid success, and genes of interest connects correct.
Fig. 6 is a gene recombination bacterium abduction delivering PAGE electrophoretogram
Swimming lane 1: empty plasmid bacterium;
Swimming lane 2: gene recombination bacterium is induced preceding (0hr);
Swimming lane 3-5: gene recombination bacterium induces 1,2,5hr;
Swimming lane 6: protein molecular weight standard (Marker).Gene recombination bacterium is through the protein expression band of increase is arranged at molecular weight 43KDa place after inducing, and is consistent with the destination protein molecular weight.Analyze through UVP image scanning, induce 5 hours destination protein expressions about 50%.
Fig. 7 is a destination protein Stx2B-Intimin-C inclusion body washing PAGE electrophoretogram
Swimming lane 1: induce the broken bacterium liquid of back gene recombination bacterium
Swimming lane 2: sky
Swimming lane 3: broken bacterium supernatant
Swimming lane 4: inclusion body cleaning mixture A (washing back)
Swimming lane 5: inclusion body cleaning mixture B (washing back)
Swimming lane 6～8: solubilization of inclusion bodies liquid 15 μ L, 10 μ L, 8 μ L electrophoresis result show that destination protein is the inclusion body formal representation, and inclusion body washing purification destination protein is respond well: in the washing process destination protein loss little, the destination protein of acquisition reaches 65% through UVP scanning analysis purity.
Fig. 8 is a destination protein Stx2B-Intimin-C purification effect PAGE electrophoretogram
Swimming lane 1: solubilization of inclusion bodies liquid (sample before the purification);
Swimming lane 2: sky;
Swimming lane 7: protein molecular weight standard (Marker).
The result shows through purification step, the purity of destination protein be improved significantly, the destination protein peak of results reaches 85-99% through UVP scanning analysis purity.
Fig. 9, Figure 10 are that N terminal amino acid sequencer map sequencing result and the implementation sequence of destination protein Stx2B-Intimin-C is in full accord.
The specific embodiment
Below in conjunction with drawings and Examples the present invention is further described.
1. enterorrhagia Bacillus coil 0157: H7 (EHEC O157:H7) derives from Chinese biological goods calibrating institute (strain number: 44828)
2. shake a bottle 150rpm incubated overnight.Get 5mL bacterium liquid 10000rpm and removed supernatant in centrifugal 5 minutes, add 0.5mL distilled water mixing and boiled 10 minutes, the samely get supernatant after centrifugal and make template.
3. adopt the encoding gene of PCR method from EHEC O157:H7 genome amplification Stx2B and Intimin-C.
1) design of primers synthetic following (underscore shows restriction enzyme site)
According to Stx2B (ACCESSION NC_000902) and Intimin (ACCESSIONZ11541) gene order and the synthetic principle design of the primer primer that GenBank announces, introduce restriction enzyme site.The linker sequential design at 3 ' end of upstream gene (Stx2B) and introduce the BamHI site, can correctly be connected two genes with the sticky end of BamHI enzyme action.
Stx2B?P1?5’-gaattc
ccatggggcatgaagaagatgttta-3’(NcoI)
P2?5’-
gaattcgctgccaccaccgccgtcattattaaact-3’(BamHI)
Stx2B-Intimin-C：
Intimin-C?P3?5’-gt
gaattcacttcagcacttaat-3’(BamHI)
P4?5’-a
aagcttttctacacaaaccgcata-3’(HindIII)
2) pcr amplification of genes of interest:
With enterohemorrhagic Escherichia coli EHEC O157:H7 genomic DNA (boiling brokenly the bacterium supernatant) is template, with P1 and P2, P3 and P4 increase respectively Stx2B and Intimin-C gene, adopt following PCR system and program:
In one 500 μ l microcentrifugal tubes, add following reagent:
10 * PCR buffer (containing magnesium chloride), 5 μ l
dNTPs(10mmol/L) 4μl
Each 1 μ l of upstream and downstream primer (0.025mmol/L)
Taq archaeal dna polymerase (5u/ μ l) 1 μ l
Add deionized water to final volume 50 μ l
Mix the back and add 3 in mineral oil
Reaction condition: 94 ℃ of pre-degeneration are after 5 minutes, and 94 ℃, 90s; 60 ℃, 60s; 72 ℃, 90s, 35 cycle periods, 72 ℃ are extended 10min then.
4.PCR the clone of product
Adopt TA cloning process clone PCR products, method is seen document, and (Yang Guizhen: TA clone and double-stranded DNA check order, and introduce the method for a kind of quick clone and analysis PCR product, Chinese Journal of Immunology, 1994,10 (1): 5) for Yu Yongli, numb red brightness.
5.PCR the sequence analysis of product
The TA clone is transformed bacterial strain deliver to company, (J.Sambrook, molecular cloning, the 1989 polyacrylamide gel electrophoresis 1.21-1.32 of publishing house of cold spring harbor laboratory) extract plasmid according to a conventional method, adopt the terminal cessation method of two deoxidations, carry out sequencing inserting fragment.
The pcr amplification effect as shown in Figure 1.
1. construction of recombinant plasmid
Stx2B is connected with carrier pMD-18T after reclaiming purification through 1.0% sepharose electrophoresis, glue with Intimin-C gene amplification (PCR) product, transformed into escherichia coli DH5 α extracts plasmid, uses Nco I and BamH I respectively, BamH I and HindIII enzyme action, 1.0% agarose gel electrophoresis is identified.
PMD-18T carrier and pET-28a (+) the BamH I and the Hind III enzyme action that will contain the Intimin-C genes of interest, the enzyme action product is after 2.0% sepharose electrophoresis, purpose fragment glue reclaim purification, connect with ligase, transformed into escherichia coli DH5 α, extract plasmid, BamH I and Hind III enzyme action, 2.0% agarose gel electrophoresis is identified.
PMD-18T carrier and pET-28a (+) the Nco I and the BamH I enzyme action that will contain the Stx2B genes of interest, the enzyme action product is after 2.0% sepharose electrophoresis, purpose fragment glue reclaim purification, connect with ligase, transformed into escherichia coli DH5 α, extract plasmid, use Nco I and BamH I enzyme action respectively, 2.0% agarose gel electrophoresis is identified.The enzyme action qualification result as shown in Figure 2.
Relevant operation concrete steps are as follows:
1) plasmid DNA extracting (using Omega company plasmid extraction test kit)
[1] separates good bacterium colony transferred species on the picking flat board in being with corresponding antibiotic LB culture fluid, 37 ℃ of shaking table overnight incubation.
[2] get bacterium liquid and be sub-packed in the 1.5mL centrifuge tube, the centrifugal 3min of 12000g leaves and takes precipitation.
[3] every pipe adds 100 μ L Solution I suspension, and mixing fully vibrates.
[4] add 100 μ L SolutionII, soft mixing, ice-water bath 5min.
[5] add 250 μ L SolutionIII, the mixing that gently shakes, room temperature is placed 10min.
[6] 4 ℃, the centrifugal 10min of 12000g move to supernatant in the separator tube.
[7] the centrifugal 1min of 12000g topples over the waste liquid in the collecting pipe.
[8] add 500 μ L washing buffer in separator tube, the same centrifugal and discard waste liquid in the collecting pipe.Repeated washing once.
[9] the centrifugal 1min of 12000g volatilizees ethanol fully.
[10] separator tube is placed another clean EP pipe and add a certain amount of TE buffer, 65 ℃ of water-bath 5min, the centrifugal 1min of 12000g.
[11] get a certain amount of eluent and carry out electrophoresis, all the other place-20 ℃ of preservations standby.
2) agarose gel electrophoresis:
1.0% agarose gel, 1 * TAE buffer, 120-150mA, electrophoresis 20-40 minute.
50 * TAE storage liquid prescription: 2.0mol/L Tris base, 1.0mol/L NaAc, 0.1mol/L Na
2EDTA; Regulate pH8.3 with glacial acetic acid.
3) endonuclease reaction of plasmid DNA:
1 μ g plasmid DNA
1 μ l, 10 * buffer (seeing Takara company product description)
1 μ l restricted enzyme Nco I or BamH I (10u/ μ l)
1 μ l restricted enzyme BamH I or Hind III (10u/ μ l)
With distilled water polishing to 10 μ l
Mixed back 37 ℃ of incubation 2-3 hours.
4) target DNA of sepharose electrophoresis glue reclaims purification:
Under uviol lamp, observe and downcut the target DNA electrophoresis band on the agarose gel, move into 1.5mL EP pipe.
Add Omega company glue and reclaim the DNA binding buffer of test kit, 65 ℃ of water-baths are dissolved gel fully and are kept pH value of solution between 5.0～6.0.Sol solutions is moved into separator tube, and the centrifugal 1min of 12000g discards the liquid in the collecting pipe.
Add supporting Washing buffer, the centrifugal 1min of 12000g discards the liquid in the collecting pipe.Repeated washing 1 time.
The centrifugal 1min of 12000g, another clean 1.5mL EP pipe of separator tube dislocation, the TE buffer of adding certain volume is hatched 10min for 65 ℃, and the centrifugal 1min of 12000g gets a certain amount of electrophoresis, and the UVP ultraviolet scanner detects and reclaims purification effect.
5) coupled reaction (using Takara company to connect test kit)
By the concentration of UV spectrophotometer measuring target DNA fragment and carrier segments, be generally 1: 2～10 principle according to external source fragment and carrier mole ratio, design coupled reaction system is as follows:
Target DNA 1 μ L
ligation?solution 5μL
ddH
2O 2～3μL
Total?volume 10μL
16 ℃ connect 12-16h.
6) preparation (CaCl of competence bacteria
2Method)
(1) the aseptic inoculation ring dips in and gets-70 ℃ of frozen antibacterials guarantor kind of liquid, and the trilinear method streak inoculation was cultivated 12～16 hours for 37 ℃ in the LB flat board.
(2) the single colony inoculation of picking is in 2mL LB culture fluid, and 37 ℃ of shaking tables are cultivated 12～16h.
(3) with the DH5a of incubated overnight in 1% ratio transferred species to the LB culture fluid, 37 ℃ of shaking tables are cultured to OD
600Be 0.2～0.4 o'clock, the centrifugal 5min of 8000g collects antibacterial.
(4) the 0.1M CaCl of adding 1mL pre-cooling
2Resuspended precipitation, ice-water bath 3h.4 ℃ of centrifugal 5min of 8000g abandon supernatant.The 0.1M CaCl that adds 100 μ L pre-coolings
2Suspend and precipitate, ice-water bath 1h, standby.
7) connecting product transforms
(1) gets competence bacteria liquid 100 μ L, add the coupled reaction product; Ice-water bath 60min, 42 ℃ of water-bath heat shock 100s place ice-water bath 1～2min rapidly.
(2) add 100 μ L LB culture fluid, 37 ℃ of shaking tables are cultivated 1h.
(3) with the centrifugal 10min of 8000g, mixing precipitated after 100 μ L supernatants were abandoned in suction, respectively got 50 μ L spread plates, 37 ℃ of incubator overnight incubation.
2. efficiently express the structure and the screening of fusion rotein engineering bacteria
To contain recombiant plasmid pET-28a (+) the transformed into escherichia coli BL21 of Stx2B and Intimin-C gene respectively and extract plasmid enzyme restriction and identify.The plasmid extraction enzyme action of the competence bacteria preparation of gene engineering colibacillus BL21, conversion and reorganization bacterium is identified the same.
Get and identify that errorless reorganization bacterium is inoculated in 3mL and contains in the LB culture fluid of Kan 37 ℃ of shaking table overnight incubation.Contain the recombination engineering of incubated overnight in the LB culture fluid of Kan in 20mL in 1% ratio transferred species next day, and 37 ℃ of shaking tables were cultivated 2.5 hours, induced 4 hours with IPTG, and SDS-PAGE detects Expression of Fusion Protein form and expression, the screening efficient expression strain.
Abduction delivering and expression way qualification result are shown in accompanying drawing 3,4.
The structure of embodiment 3 fusion gene expression plasmids and efficiently express the structure and the screening of fusion rotein engineering bacteria
1. construction of recombinant plasmid
Stx2B is connected with carrier pMD-18T after reclaiming purification through 1.0% sepharose electrophoresis, glue with Intimin-C gene amplification (PCR) product, transformed into escherichia coli DH5 α extracts plasmid, uses Nco I and BamH I respectively, BamH I and HindIII enzyme action, 1.0% agarose gel electrophoresis is identified.
PMD-18T carrier and pET-28a (+) the BamH I and the Hind III enzyme action that will contain the Intimin-C genes of interest, the enzyme action product is after 2.0% sepharose electrophoresis, purpose fragment glue reclaim purification, connect with ligase, transformed into escherichia coli DH5 α, extract plasmid, BamH I and Hind III enzyme action, 2.0% agarose gel electrophoresis is identified.
The pET-28a (+) that will contain the pMD-18T carrier of Stx2B genes of interest and contain the Intimin-C genes of interest is with Nco I and BamH I enzyme action, the enzyme action product is after 2.0% sepharose electrophoresis, purpose fragment glue reclaim purification, connect with ligase, transformed into escherichia coli DH5 α extracts plasmid, uses Nco I and BamH I respectively, BamH I and Hind III, Nco I and HindIII enzyme action, 1.0% agarose gel electrophoresis identifies that the enzyme action qualification result as shown in Figure 5.
Relevant operation concrete steps are the same.
2. efficiently express the structure and the screening of fusion rotein engineering bacteria
To contain recombiant plasmid pET-28a (+) the transformed into escherichia coli BL21 of Stx2B-Intimin-C fusion gene and extract the plasmid enzyme restriction evaluation.The plasmid extraction enzyme action of the competence bacteria preparation of gene engineering colibacillus BL21, conversion and reorganization bacterium is identified the same.
Get and identify that errorless reorganization bacterium is inoculated in 3mL and contains in the LB culture fluid of Kan 37 ℃ of shaking table overnight incubation.Contain the recombination engineering of incubated overnight in the LB culture fluid of Kan in 20mL in 1% ratio transferred species next day, and 37 ℃ of shaking tables were cultivated 2.5 hours, induced 4 hours with IPTG, and SDS-PAGE detects Expression of Fusion Protein form and expression, the screening efficient expression strain.
Abduction delivering and expression way qualification result are as shown in Figure 6.
The fermentation of embodiment 4 gene recombination bacteriums
Fermentation technology is as follows:
Adopt German B.Bron 10L fermentation tank, plant the inoculation of daughter bacteria 10% ratio in the sweat, keep 70% dissolved oxygen, 37 ℃ of temperature, pH7.0, do not reach at 2 o'clock at A600 and do not add feed supplement, every afterwards 0.5h flow feeding once makes the final concentration of glucose, tryptone and 8% yeast extract be respectively 0.5%, 0.2% and 0.2%.Treat after the 4th feed supplement that concentration of glucose is reduced at 0.1% o'clock and added IPTG 500 μ mol/L and induce 4h to receive bacterium.
Sweat on the batch culture basis of cascade dissolved oxygen control, flow feeding.
The used culture medium of sweat is added 0.6% yeast leachate and 2mg/L ZnCl for improvement M9-CAA culture medium on the basis of M9-CAA
24H
2O, 2mg/LCoCl
24H
2O, 4mg/L FeSO
416H
2O, 5mg/L H
3BO
3, 1.6mg/LMnCl
24H
2O, 4mg/L CuSO
4Form.
Reclaim bacterium liquid, 4 ℃ centrifugal (8000g) 15 minutes after the fermentation ends.Supernatant is abandoned in suction, collects antibacterial, and the back of weighing is frozen standby.
The result: the 10L zymocyte liquid can be gathered in the crops antibacterial weight in wet base 800 grams.
The purification of embodiment 5 recombiant proteins
1. inclusion body extracts: the thalline 200-500g that efficiently expresses is suspended with 1: 10 (W/V) ratio of TE buffer, adopt the cell homogenates machine to make its mix homogeneously after 4 ℃ of pre-coolings.Adopting high pressure homogenizer is break bacterium (breaking bacterium 4～6 times altogether) under the condition of 40-70Mpa at pressure, after broken bacterium finishes, bacterium liquid smear staining takes a morsel, the integrity of microscopically observation of cell guarantees that cell breakage is complete, subsequently with the centrifugal 25min of 500g, abandon precipitation, with 15, the centrifugal 40min of 000g abandons the supernatant collecting precipitation again.Ratio with 1: 10 (W/V) is respectively washed 2 times with cleaning mixture A and B respectively.Wash conditions is: 4 ℃ are stirred 20min, and 15, the centrifugal 40min of 000g collects the inclusion body precipitation; At last inclusion body is used the mixed of solubilization of inclusion bodies liquid with 1: 10 (W/V), 4 ℃ are stirred 3h, and 15, the centrifugal 45min of 000g gets the raw material of supernatant as next step purification.
Inclusion body extracts used buffer:
1) TE buffer: 20mmol/L Tris, 5mmol/L EDTA, pH 8.5
2) inclusion body cleaning mixture A:5mmol/L EDTA, 20mmol/L Tris, 1%Triton X-100, pH8.5
3) inclusion body cleaning mixture B:20mmol/L Tris, 2mol/L Urea, pH8.5
4) solubilization of inclusion bodies liquid: 1mmol/L EDTA, 20mmol/L Tris, 8mol/L carbamide (pH8.5)
2. anion column purification: select anion column HiTrap Q to carry out purification, use 10mmol/L PB, 8mol/L Urea carries out purification to destination protein under the PH11 condition, adopt the NaCl gradient elution.
3.Superdex gel permeation chromatography purification: step (3) target protein that obtains in glucosan PEG bag filter, concentrate or ultrafiltration and concentration after with solvent resistant column Superdex purification, with gel filtration level pad balance.
4. purified target protein is carried out SDS-PAGE, examines and determine its purity.The Lowry method detects protein concentration.
Wherein, the height that uses in described employing production of step 1 or the pilot scale purification crushes the bacterium technology, and broken bacterium to antibacterial is cracked rate greater than 98%, and differential centrifugation obtains the inclusion body precipitate.
The described anion purification of step 2 filler is one of Q Sepharose HP, Q Sepharose FF, Q Sepharose XL.
The described used gel permeation chromatography post of step 3 is one of Superdex 75, Superdex 200, Superdex HR 10/30.
The inclusion body wash result as shown in Figure 7, purification result is as shown in Figure 8.
The N end order-checking of embodiment 6 destination proteins
With partially purified destination protein Stx2B-Intimin-C behind the SDS-PAGE electrophoresis electrotransfer to pvdf membrane, coomassie brilliant blue staining and decolour clear to the purpose band, cut the purpose band, deliver to central laboratory of Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and carry out 15 amino acid sequencings of destination protein N end.
15 aminoacid of sequencing result N end and implementation sequence are in full accord.Sequencing result is shown in accompanying drawing 9, accompanying drawing 10.
Embodiment 7 animal immunes and antibody test
Destination protein is through immune Balb/c mice behind the purification, and 100ug/, 100 μ L antigens mix with equivalent Al (OH) 3 adjuvants, injection mouse web portion and the subcutaneous immunity of groin.Once in a week, respectively at the 4 day blood samplings of immunity after 3,4 times, ELISA detects the change of serological specificity antibody titer.
Antibody positive rate after the result immunity 3 times is 90%, and the antibody positive rate after the immunity 4 times reaches 98%.
The counteracting toxic substances protection of embodiment 8 immune animals
Immunization protocol with embodiment 6, adopted the ultrasonic supernatant of O157 bacterium of fatal dose (to contain Stx2 toxin and other morbid substance in the 10th day after immune 4 times, protein concentration 1mg/mL) the 0.05mL lumbar injection carries out the counteracting toxic substances experiment to immune mouse and control mice, observe the death condition of respectively organizing mice, after 30 days observation period, calculate the death/survival rate such as the table 1 of immune mouse.
The subcutaneous immune mouse of table 1 Stx2B-Intimin-C, the ultrasonic supernatant counteracting toxic substances-immune protective effect of O157 bacterium
Death condition behind the counteracting toxic substancesDeposit survival rate after 30 days
Group quantity alive (protection in 3 days 4 days 5 days 6 days 7～30
It rate)
Stx2B-Intimin-C
0 2 1 1 0 46 92％
Immune group (50)
Matched group (50) 0 39 11 0000
The result shows that the protective rate of immune group mice reaches more than 90%.
Conclusion: vaccine antigen Stx2B-Intimin-C immune mouse, can attack at O157 mushroom toxin material and produce effective protective effect.
The vaccine therapy of embodiment 9 infection animals is observed
With high concentration EHEC O157 culture (10
9Cfu) irritate through stomach and raise the Balb/c mice, irritated the stomach treatment to raising the bacterium mice once a day in continuous two days with vaccine antigen Stx2B-Intimin-C 100ug (100uL)/only or equal-volume PBS behind the 48hr.Observe the treatment back mice discharge of bacteria time.
The discharge of bacteria time observed after the bacterium mice was raised in table 2 Stx2B-Intimin-C treatment
Mice stops the discharge of bacteria natural law in the treatment backEqual discharge of bacteria maintained an equal level after 10 days
Between the continuous discharge of bacteria of group 3 days 4 days 5 days 6 days 7～10 hour (my god)
It Mus quantity
Stx2B-Intimin-C
Treatment group (50) 10 22 8640 4.6
Matched group (50) 01344 38＞10
Two groups of results credit by statistics analyse p＜0.001.Illustrate that vaccine antigen Stx2B-Intimin-C irritates stomach treatment and can effectively shorten the microbiological contamination mice discharge of bacteria time raising the bacterium mice.
Conclusion: vaccine antigen Stx2B-Intimin-C infects the O157 bacterium certain therapeutical effect.
Sequence table
SEQ?ID?NO：1
＜110〉Military Medical Univ No.3, P.L.A
＜120〉genetic engineering multivalent subunit vaccine of prevention of people and susceptible animal O157 bacterium infection immunity and therapeutic use and preparation method thereof
<130>
<160>3
<170>Patent?In?version?3.2
<210>1
<211>1200
<212>DNA
＜213〉enterorrhagia Bacillus coil 0157: H7 (Enterohemorrhagic E.coliO157:H7, EHEC O157:H7) native sequences manually merges reconstruction
<220>
<221>misc_feature
<222>(1)…(1200)
<400>1
ATGGGCATGA?AGAAGATGTT?TATGGCGGTT?TTATTTGCAT?TAGCTTCTGT?TAATGCAATG 60
GCGGCGGATT?GTGCTAAAGG?TAAAATTGAG?TTTTCCAAGT?ATAATGAGGA?TGACACATTT 120
ACAGTGAAGG?TTGACGGGAA?AGAATACTGG?ACCAGTCGCT?GGAATCTGCA?ACCGTTACTG 180
CAAAGTGCTC?AGTTGACAGG?AATGACTGTC?ACAATCAAAT?CCAGTACCTG?TGAATCAGGC 240
TCCGGATTTG?CTGAAGTGCA?GTTTAATAAT?GACGGCGGTG?GTGGCAGCCA?TATGACTTCA 300
GCACTTAATG?CCAGTGCGGT?TATATTTTTT?GATCAAACCA?AGGCCAGCAT?TACTGAGATT 360
AAGGCTGATA?AGACAACTGC?AGTAGCAAAT?GGTAAGGATG?CTATTAAATA?TACTGTAAAA 420
GTTATGAAAA?ACGGTCAGCC?AGTTAATAAT?CAATCCGTTA?CATTCTCAAC?AAACTTTGGG 480
ATGTTCAACG?GTAAGTCTCA?AACGCAAGCA?ACCACGGGAA?ATGATGGTCG?TGCGACGATA 540
ACACTAACTT?CCAGTTCCGC?CGGTAAAGCG?ACTGTTAGTG?CGACAGTCAG?TGATGGGGCT 600
GAGGTTAAAG?CGACTGAGGT?CACTTTTTTT?GATGAACTGA?AAATTGACAA?CAAGGTTGAT 660
ATTATTGGTA?ACAACGTCAG?AGGCGAGTTG?CCTAATATTT?GGCTGCAATA?TGGTCAGTTT 720
AAACTGAAAG?CAAGCGGTGG?TGATGGTACA?TATTCATGGT?ATTCAGAAAA?TACCAGTATC 780
GCGACTGTCG?ATGCATCAGG?GAAAGTCACT?TTGAATGGTA?AAGGCAGTGT?CGTAATTAAA 840
GCCACATCTG?GTGATAAGCA?AACAGTAAGT?TACACTATAA?AAGCACCGTC?GTATATGATA 900
AAAGTGGATA?AGCAAGCCTA?TTATGCTGAT?GCTATGTCCA?TTTGCAAAAA?TTTATTACCA 960
TCCACACAGA?CGGTATTGTC?AGATATTTAT?GACTCATGGG?GGGCTGCAAA?TAAATATAGC 1020
CATTATAGTT?CTATGAACTC?AATAACTGCT?TGGATTAAAC?AGACATCTAG?TGAGCAGCGT 1080
TCTGGAGTAT?CAAGCACTTA?TAACCTAATA?ACACAATACC?CTCTTCCTGG?GGTTAATGTT 1140
AATACTCCAA?ATGTCTATGC?GGTTTGTGTA?GAAAAGCTTC?ACCACCACCA?CCACCACTGA 1200
SEQ?ID?NO：2
<210>2
<211>399
<212>PRT
＜213〉aminoacid sequence of Stx2B-Intimin-C fusion rotein
<220>
<221>INIT_MET
<222>(1)…(399)
<400>1
MetGlyMetLysLys?MetPheMetAlaVal?LeuPheAlaLeuAla?15
SerValAsnAlaMet?AlaAlaAspCysAla?LysGlyLysIleGlu?30
PheSerLysTyrAsn?GluAspAspThrPhe?ThrValLysValAsp?45
GlyLysGluTyrTrp?ThrSerArgTrpAsn?LeuGlnProLeuLeu?60
GlnSerAlaGlnLeu?ThrGlyMetThrVal?ThrIleLysSerSer?75
ThrCysGluSerGly?SerGlyPheAlaGlu?ValGlnPheAsnAsn?90
AspGlyGlyGlyGly?SerHisMetThrSer?AlaLeuAsnAlaSer?105
AlaValIlePhePhe?AspGlnThrLysAla?SerIleThrGluIle?120
LysAlaAspLysThr?ThrAlaValAlaAsn?GlyLysAspAlaIle?135
LysTyrThrValLys?ValMetLysAsnGly?GlnProValAsnAsn?150
GlnSerValThrPhe?SerThrAsnPheGly?MetPheAsnGlyLys?165
SerGlnThrGlnAla?ThrThrGlyAsnAsp?GlyArgAlaThrIle?180
ThrLeuThrSerSer?SerAlaGlyLysAla?ThrValSerAlaThr?195
ValSerAspGlyAla?GluValLysAlaThr?GluValThrPhePhe?210
AspGluLeuLysIle?AspAsnLysValAsp?IleIleGlyAsnAsn?225
ValArgGlyGluLeu?ProAsnIleTrpLeu?GlnTyrGlyGlnPhe?240
LysLeuLysAlaSer?GlyGlyAspGlyThr?TyrSerTrpTyrSer?255
GluAsnThrSerIle?AlaThrValAspAla?SerGlyLysValThr?270
LeuAsnGlyLysGly?SerValValIleLys?AlaThrSerGlyAsp?285
LysGlnThrValSer?TyrThrIleLysAla?ProSerTyrMetIle?300
LysValAspLysGln?AlaTyrTyrAlaAsp?AlaMetSerIleCys?315
LysAsnLeuLeuPro?SerThrGlnThrVal?LeuSerAspIleTyr?330
AspSerTrpGlyAla?AlaAsnLysTyrSer?HisTyrSerSerMet?345
AsnSerIleThrAla?TrpIleLysGlnThr?SerSerGluGlnArg?360
SerGlyValSerSer?ThrTyrAsnLeuIle?ThrGlnTyrProLeu?375
ProGlyValAsnVal?AsnThrProAsnVal?TyrAlaValCysVal?390
GluLeuGluHisHis?HisHisHisHis 399
SEQ?ID?NO：3
<210>3
<211>909
<212>DNA
＜213〉enterorrhagia Bacillus coil 0157: H7 (Enterohemorrhagic E.coliO157:H7, EHEC O157:H7)
<400>1
ATGACTTCAG?CACTTAATGC?CAGTGCGGTT?ATATTTTTTG?ATCAAACCAA?GGCCAGCATT 60
ACTGAGATTA?AGGCTGATAA?GACAACTGCA?GTAGCAAATG?GTAAGGATGC?TATTAAATAT 120
ACTGTAAAAG?TTATGAAAAA?CGGTCAGCCA?GTTAATAATC?AATCCGTTAC?ATTCTCAACA 180
AACTTTGGGA?TGTTCAACGG?TAAGTCTCAA?ACGCAAGCAA?CCACGGGAAA?TGATGGTCGT 240
GCGACGATAA?CACTAACTTC?CAGTTCCGCC?GGTAAAGCGA?CTGTTAGTGC?GACAGTCAGT 300
GATGGGGCTG?AGGTTAAAGC?GACTGAGGTC?ACTTTTTTTG?ATGAACTGAA?AATTGACAAC 360
AAGGTTGATA?TTATTGGTAA?CAACGTCAGA?GGCGAGTTGC?CTAATATTTG?GCTGCAATAT 420
GGTCAGTTTA?AACTGAAAGC?AAGCGGTGGT?GATGGTACAT?ATTCATGGTA?TTCAGAAAAT 480
ACCAGTATCG?CGACTGTCGA?TGCATCAGGG?AAAGTCACTT?TGAATGGTAA?AGGCAGTGTC 540
GTAATTAAAG?CCACATCTGG?TGATAAGCAA?ACAGTAAGTT?ACACTATAAA?AGCACCGTCG 600
TATATGATAA?AAGTGGATAA?GCAAGCCTAT?TATGCTGATG?CTATGTCCAT?TTGCAAAAAT 660
TTATTACCAT?CCACACAGAC?GGTATTGTCA?GATATTTATG?ACTCATGGGG?GGCTGCAAAT 720
AAATATAGCC?ATTATAGTTC?TATGAACTCA?ATAACTGCTT?GGATTAAACA?GACATCTAGT 780
GAGCAGCGTT?CTGGAGTATC?AAGCACTTAT?AACCTAATAA?CACAATACCC?TCTTCCTGGG 840
GTTAATGTTA?ATACTCCAAA?TGTCTATGCG?GTTTGTGTAG?AAAAGCTTCA?CCACCACCAC 900
CACCACTGA?909
Claims (8)
1. the genetic engineering multivalent subunit vaccine of prevention of people and susceptible animal O157 bacterium infection immunity and therapeutic use is characterized in that: the protective antigen subunit that comprises two or more enterohemorrhagic Escherichia coli (EHEC) O157 at least.
2. O157 bacterium genetic engineering multivalent subunit vaccine according to claim 1; it is characterized in that: its vaccine antigen component be enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion element (Intimin), shiga toxin I in conjunction with subunit (Stx1B), shiga toxin II in conjunction with subunit (Stx2B), EHEC hemolysin (haemolysin; hly) and separately immune protective fragment; or the compositions of its peptide mimics; or any two or more antigenic compositions wherein, or add other any antigen component on this basis and the compositions that forms.
3. according to claim 1,2 described O157 bacterium genetic engineering multivalent subunit vaccine, it is characterized in that: this vaccine antigen be enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion element (Intimin), shiga toxin I in conjunction with subunit (Stx1B), shiga toxin II in conjunction with subunit (Stx2B), EHEC hemolysin (haemolysin, hly) by gene cloning and expression, its destination protein purified product is with the mixture of particular combinations and mixed.
4. according to claim 1,2 described O157 bacterium genetic engineering multivalent subunit vaccine, it is characterized in that: this vaccine antigen is enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion element (Intimin), shiga toxin I (haemolysin hly) merges with particular combinations and connected mode and the genetic engineering recombination fusion protein that obtains at gene level in conjunction with subunit (Stx2B), EHEC hemolysin in conjunction with subunit (Stx1B), shiga toxin II.
5. according to claim 1,2 described O157 bacterium genetic engineering multivalent subunit vaccine, it is characterized in that: this vaccine antigen be enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion element (Intimin), shiga toxin I in conjunction with subunit (Stx1B), shiga toxin II in conjunction with subunit (Stx2B), EHEC hemolysin (haemolysin, hly) gene level merge with particular combinations and connected mode and the genetic engineering recombination fusion protein that obtains each other and with the mixture of any subunit monomer with various combination and mixed.
6. the bacterin preparation that adopts O157 bacterium genetic engineering multivalent subunit vaccine antigen to obtain, it is characterized in that: this bacterin preparation comprises any one the genetic engineering multivalent subunit vaccine antigen of claim 1-5 as activating agent with medicine effective quantity, and acceptable diluent, carrier and/or adjuvant in the bacterin preparation.
7. bacterin preparation according to claim 6 is characterized in that: this bacterin preparation is a genetic engineering multivalent subunit protein vaccine, is suitable for by mucosa, gastrointestinal approach, subcutaneous and intramuscular injection path administration.
8. preparation comprises the steps: according to the method for any one described vaccine of claim 1-5
1) cultivates enterohemorrhagic Escherichia coli O 157:H7 (EHEC O157);
2) encoding gene of Intimin, Stx1B, Stx2B and the hly of clone's enterohemorrhagic Escherichia coli O 157:H7
(1) with the encoding gene of Intimin, Stx1B, Stx2B and the hly of PCR method amplification EHEC O157
(2) clone of PCR product
(3) sequence analysis of PCR product;
3) the procaryotic cell expression plasmid and the fusion gene expression plasmid of structure Intimin, Stx1B, Stx2B and hly gene
(1) cloned plasmids of usefulness restriction enzyme enzyme action Intimin, Stx1B, Stx2B and hly
(2) the enzyme action product separates through agarose gel electrophoresis
(3) the target DNA electrophoresis band on the cutting-out agarose gel
(4) genes of interest is reclaimed product is cloned respectively or be cloned into procaryotic cell expression plasmid and transformed into escherichia coli with various combination and order;
4) sequence of mensuration fusion gene;
5) induced gene recombination engineering expresses obtaining destination protein;
6) the N terminal amino acid sequence of destination protein is analyzed;
7) purifies and separates destination protein adopts ion exchange column, affine and hydrophobic chromatography post or gel permeation chromatography post that destination protein is carried out purification;
8) purity of evaluation destination protein;
This destination protein and each other different compositionss be enterohemorrhagic Escherichia coli (EHEC) O157 tight adhesion element, shiga toxin I in conjunction with subunit (Stx1B), shiga toxin II in conjunction with subunit (Stx2B) and EHEC hemolysin (hly) and the segmental genetic engineering multivalent subunit vaccine antigen of immune protective thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100320260A CN1305525C (en) | 2004-03-27 | 2004-03-27 | 0157 bacterium gene engineering multivalence subunit vaccine of human and sensitive animals and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100320260A CN1305525C (en) | 2004-03-27 | 2004-03-27 | 0157 bacterium gene engineering multivalence subunit vaccine of human and sensitive animals and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1631438A true CN1631438A (en) | 2005-06-29 |
| CN1305525C CN1305525C (en) | 2007-03-21 |
Family
ID=34845717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100320260A Expired - Fee Related CN1305525C (en) | 2004-03-27 | 2004-03-27 | 0157 bacterium gene engineering multivalence subunit vaccine of human and sensitive animals and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1305525C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101830985A (en) * | 2010-03-05 | 2010-09-15 | 江苏省农业科学院 | Recombination protein of enterohemorrhagic Escherichia coli O157:H7Tir and Tccp |
| CN102114241A (en) * | 2010-09-26 | 2011-07-06 | 中国人民解放军第三军医大学 | Attenuated live vaccine and application thereof |
| CN101357942B (en) * | 2008-05-30 | 2012-01-04 | 中国人民解放军第三军医大学 | Monoclonal antibody, Fab antibody and application for neutralizing enterohemorrhagic escherichia coli o157:H7 shiga toxin II |
| CN101691406B (en) * | 2009-09-09 | 2012-02-08 | 中国人民解放军军事医学科学院微生物流行病研究所 | New fusion protein SSI, application and special gene thereof |
| WO2012037779A1 (en) * | 2010-09-25 | 2012-03-29 | 中国人民解放军军事医学科学院微生物流行病研究所 | FUSION PROTEIN SAmB, CODING GENE AND APPLICATION THEREOF |
| CN102747024A (en) * | 2012-06-19 | 2012-10-24 | 江苏省农业科学院 | EHEC 0157:H7 multivalent fliC-hcpA-tir-eae recombinant strain and vaccine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1203819A (en) * | 1997-04-23 | 1999-01-06 | 株式会社源 | Prevention and treatment of Enterohemorrhagic Escherichia coli (EHEC) infection |
| US6594175B2 (en) * | 2000-07-11 | 2003-07-15 | Integrated Magnetoelectronics Corp | High density giant magnetoresistive memory cell |
| AU2002241162A1 (en) * | 2001-03-29 | 2002-10-15 | Imperial College Innovations Limited | Intimins in the prevention or treatment of infections:ii |
-
2004
- 2004-03-27 CN CNB2004100320260A patent/CN1305525C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101357942B (en) * | 2008-05-30 | 2012-01-04 | 中国人民解放军第三军医大学 | Monoclonal antibody, Fab antibody and application for neutralizing enterohemorrhagic escherichia coli o157:H7 shiga toxin II |
| CN101691406B (en) * | 2009-09-09 | 2012-02-08 | 中国人民解放军军事医学科学院微生物流行病研究所 | New fusion protein SSI, application and special gene thereof |
| CN101830985A (en) * | 2010-03-05 | 2010-09-15 | 江苏省农业科学院 | Recombination protein of enterohemorrhagic Escherichia coli O157:H7Tir and Tccp |
| CN101830985B (en) * | 2010-03-05 | 2012-04-25 | 江苏省农业科学院 | Recombination protein of enterohemorrhagic Escherichia coli O157:H7Tir and Tccp |
| WO2012037779A1 (en) * | 2010-09-25 | 2012-03-29 | 中国人民解放军军事医学科学院微生物流行病研究所 | FUSION PROTEIN SAmB, CODING GENE AND APPLICATION THEREOF |
| CN102114241A (en) * | 2010-09-26 | 2011-07-06 | 中国人民解放军第三军医大学 | Attenuated live vaccine and application thereof |
| CN102114241B (en) * | 2010-09-26 | 2012-07-04 | 中国人民解放军第三军医大学 | Attenuated live vaccine and application thereof |
| CN102747024A (en) * | 2012-06-19 | 2012-10-24 | 江苏省农业科学院 | EHEC 0157:H7 multivalent fliC-hcpA-tir-eae recombinant strain and vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1305525C (en) | 2007-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1246038C (en) | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents | |
| CN1222618C (en) | Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof | |
| CN1927394A (en) | Oral administration recombinant helicobacterpylori vaccine and preparing method thereof | |
| CN1171814A (en) | Polynucleotide tuberculosis vaccine | |
| CN101062410A (en) | Genetic engineering vaccine of enterohemorrhagic escherichia coli 0157:H7 and the preparing method thereof | |
| CN101054582A (en) | A-type kreotoxin receptor combination region Hc, coding protein and application thereof | |
| CN101031647A (en) | Process for producing erysipelothrix rhusiopathiae surface protective antigen mutant in escherichia coli | |
| CN1990869A (en) | Chicken infectivity bursa of Fabricius virus VP2 cDNA, its expression vector, expressed recombinant protein and application thereof | |
| CN101033468A (en) | Helicobacter pylori urease B subunit B cell antigen epitope polypeptide, identification method and application | |
| CN1899610A (en) | Pyloric spiral bacillus antigen recombinant vaccine | |
| CN1807452A (en) | Helicobacter Pylori urease B subunit Th epitope peptide, its coding DNA, vaccine and uses | |
| CN1305525C (en) | 0157 bacterium gene engineering multivalence subunit vaccine of human and sensitive animals and its preparing method | |
| CN1833723A (en) | Chain coccus recombination subunit vaccine and prepn. thereof | |
| CN1184319C (en) | Chemosynthesized SARS virus S gene segement, its expression and application | |
| CN1191091C (en) | Novel preventives/remedies for immunopathy | |
| CN1748791A (en) | Haemorrhagic E, coli 0157:H7 vaccine for human and livestock prevention and preparing method | |
| CN1335889A (en) | Chimeric gene encoding the antigenic determinants of four proteins of L.INFANTUM | |
| CN1840546A (en) | Recombinant fusion protein with targeted cell for killing tumor | |
| CN1864746A (en) | Gene engineered poly-valence subunit vaccine of Hp AhpC and preparation method thereof | |
| CN1484700A (en) | Aop beta gene protein homologs fragments and thereof and their use for cell surface display | |
| CN1657617A (en) | Clone, expression and anti-tick immanoprotection action of falcate rhipicephalus RhcA and RhcB genes | |
| CN1280310C (en) | Fusion protein with cold proventing and curing function and its encoding gene and use | |
| CN1850977A (en) | Soluble colibacillus expression plasmid and its use | |
| CN1249240C (en) | Expression vector pBVTB, its construction method and use in HCV vaccin research | |
| CN1597956A (en) | Trans menbrance type and secretory type HIV Gag antigen code gene and AIDS vaccine containing said gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |